Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14134840 | 0.91 | MTNR1A (0.51) | MTNR1AALDH1A1HPGDKMT2APLAU | |
| SCHEMBL4485886 | 0.86 | PLAU (0.52) | PLAUTRPV1NPC1RAB9A | |
| SCHEMBL14433303 | 0.86 | TRPV1 (0.53) | MTNR1AALDH1A1HPGDKMT2APLAU | |
| SCHEMBL6468887 | 0.83 | PLAU (0.42) | MTNR1AALDH1A1HPGDKMT2APLAU | |
| SCHEMBL2676775 | 0.83 | MTNR1A (0.55) | MTNR1AALDH1A1HPGDKMT2ATRPV1 | |
| SCHEMBL487112 | 0.82 | TRPV1 (0.44) | MTNR1AALDH1A1HPGDKMT2APLAU | |
| SCHEMBL7709234 | 0.81 | TRPV1 (0.44) | ALDH1A1HPGDKMT2APLAUTRPV1 | |
| SCHEMBL487254 | 0.81 | TRPV1 (0.64) | KMT2ATRPV1MEN1NQO2RAB9A | |
| SCHEMBL31680675 | 0.81 | TRPV1 (0.64) | KMT2ATRPV1MEN1NQO2RAB9A | |
| SCHEMBL24149842 | 0.80 | TRPV1 (0.46) | MTNR1AALDH1A1HPGDPLAUTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427436-B1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-8334315-B2 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8334315-B2 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173841-B2 | Tetrahydro-naphthalene derivatives | XENTION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| EP-1885704-B1 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006122250-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | BAYER HEAITHCARE AG (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1678123-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| EP-1594836-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005040100-A1 | TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1506167-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004072020-A1 | HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-26 | — | — | WO | disclosed |
| WO-2003095420-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | HVCN1, NMUR1, OPRL1 | MTNR1A 320/4885ALDH1A1 271/4885HPGD 201/4885 |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | TRPV1, TMEM109, CACNA1E | MTNR1A 32/4885ALDH1A1 805/4885HPGD 961/4885 |
| US-20110178088-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | OPRL1, OPRK1, VAT1 | MTNR1A 227/4885ALDH1A1 541/4885HPGD 83/4885 |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | NMUR1, HVCN1, GPR17 | MTNR1A 248/4885ALDH1A1 255/4885HPGD 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.